Organism ID | Organism Name | Taxonomy Level | Family | SuperKingdom | Isolation Part | Collection Location | Collection Time | Reference |
---|---|---|---|---|---|---|---|---|
NPO1797 | Homo sapiens | Species | Hominidae | Eukaryota | saliva | DOI[10.1007/s11306-015-0840-5] | ||
NPO1797 | Homo sapiens | Species | Hominidae | Eukaryota | blood | Geigy Scientific Tables, 8th Rev edition. Edited by C. Lentner, West Cadwell, N.J.: Medical education Div., Ciba-Geigy Corp., Basel, Switzerland c1981-1992. | ||
NPO1797 | Homo sapiens | Species | Hominidae | Eukaryota | cytoplasm |
PMID[15882454] |
||
NPO1797 | Homo sapiens | Species | Hominidae | Eukaryota | cerebrospinal fluid |
PMID[15993662] |
||
NPO20338 | Mus musculus | Species | Muridae | Eukaryota |
PMID[19425150] |
|||
NPO730 | Escherichia coli | Species | Enterobacteriaceae | Bacteria |
PMID[21988831] |
Target ID | Target Type | Target Name | Target Organism | Activity Type | Activity Relation | Value | Unit | Reference |
---|---|---|---|---|---|---|---|---|
NPT4492 | Individual Protein | P2Y purinoceptor 1 | Meleagris gallopavo | EC50 | = | 2800 | nM | 12213051 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 230 | nM | 12213051 |
NPT3827 | Individual Protein | Pyrimidinergic receptor P2Y4 | Homo sapiens | EC50 | = | 43000 | nM | 12213051 |
NPT3828 | Individual Protein | Pyrimidinergic receptor P2Y4 | Rattus norvegicus | EC50 | = | 1800 | nM | 12213051 |
NPT1391 | Individual Protein | Pyrimidinergic receptor P2Y6 | Homo sapiens | EC50 | > | 100000 | nM | 12213051 |
NPT3829 | Individual Protein | Purinergic receptor P2Y11 | Homo sapiens | EC50 | = | 17000 | nM | 12213051 |
NPT4493 | Individual Protein | Purinergic receptor P2Y12 | Rattus norvegicus | EC50 | = | 3190 | nM | 12213051 |
NPT2674 | Individual Protein | P2X purinoceptor 1 | Homo sapiens | EC50 | = | 56 | nM | 12213051 |
NPT4953 | Individual Protein | P2X purinoceptor 2 | Rattus norvegicus | EC50 | = | 1400 | nM | 12213051 |
NPT2675 | Individual Protein | P2X purinoceptor 3 | Homo sapiens | EC50 | = | 340 | nM | 12213051 |
NPT4954 | Individual Protein | P2X purinoceptor 4 | Homo sapiens | EC50 | = | 500 | nM | 12213051 |
NPT2671 | Individual Protein | P2X purinoceptor 4 | Rattus norvegicus | EC50 | = | 1000 | nM | 12213051 |
NPT4494 | Individual Protein | P2X purinoceptor 5 | Rattus norvegicus | EC50 | = | 1000 | nM | 12213051 |
NPT4495 | Individual Protein | P2X purinoceptor 6 | Rattus norvegicus | EC50 | = | 1000 | nM | 12213051 |
NPT2654 | Individual Protein | P2X purinoceptor 7 | Homo sapiens | EC50 | = | 780000 | nM | 12213051 |
NPT4492 | Individual Protein | P2Y purinoceptor 1 | Meleagris gallopavo | EC50 | = | 6353 | nM | 10479295 |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Inhibition | = | 60 | % | 10411489 |
NPT1755 | Individual Protein | Thymidine kinase, cytosolic | Homo sapiens | Inhibition | = | 0 | % | 7040662 |
NPT2 | Others | Unspecified | Inhibition | = | 0 | % | 7040662 | |
NPT4956 | Individual Protein | Hexokinase type I | Rattus norvegicus | Inhibition | = | 0 | % | 7040662 |
NPT4957 | Individual Protein | Hexokinase type II | Rattus norvegicus | Inhibition | = | 0 | % | 7040662 |
NPT4958 | Individual Protein | Hexokinase type III | Rattus norvegicus | Inhibition | = | 0 | % | 7040662 |
NPT4492 | Individual Protein | P2Y purinoceptor 1 | Meleagris gallopavo | EC50 | = | 2800 | nM | 11985476 |
NPT3825 | Individual Protein | Purinergic receptor P2Y1 | Homo sapiens | EC50 | = | 1500 | nM | 11985476 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 85 | nM | 11985476 |
NPT3829 | Individual Protein | Purinergic receptor P2Y11 | Homo sapiens | EC50 | = | 17300 | nM | 11985476 |
NPT4959 | Individual Protein | Ectonucleoside triphosphate diphosphohydrolase 1 | Rattus norvegicus | Activity | = | 100 | % | 11985476 |
NPT4960 | Individual Protein | Ectonucleoside triphosphate diphosphohydrolase 2 | Rattus norvegicus | Activity | = | 100 | % | 11985476 |
NPT2 | Others | Unspecified | Kd | = | 10000 | nM | 9089334 | |
NPT4759 | Individual Protein | Adenylate kinase 2 | Rattus norvegicus | Ki | = | 90000 | nM | 6292418 |
NPT4760 | Individual Protein | Adenylate kinase 1 | Rattus norvegicus | Ki | = | 570000 | nM | 6292418 |
NPT2672 | Individual Protein | Dihydroorotase | Homo sapiens | Activity | = | 100 | % | 10.1016/0960-894X(96)00452-0 |
NPT4961 | Individual Protein | Glycerol kinase | Homo sapiens | Ki | = | 200000 | nM | 10.1016/S0960-894X(97)10051-8 |
NPT3831 | Individual Protein | Purinergic receptor P2Y1 | Rattus norvegicus | EC50 | = | 590 | nM | 15317453 |
NPT1758 | Individual Protein | Hepatitis C virus NS5B RNA-dependent RNA polymerase | Hepatitis C virus | Ratio | = | 1700 | 15828825 | |
NPT4500 | Individual Protein | Heat shock protein 90 beta | Canis lupus familiaris | EC50 | = | 19000 | nM | 16854066 |
NPT2264 | Protein Family | Heat shock protein HSP90 | Homo sapiens | EC50 | = | 1500000 | nM | 16854066 |
NPT3582 | Individual Protein | Ketopantoate reductase | Escherichia coli K-12 | Kd | = | 130000 | nM | 16884311 |
NPT3582 | Individual Protein | Ketopantoate reductase | Escherichia coli K-12 | Ki | = | 610000 | nM | 16884311 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 85 | nM | 17302398 |
NPT3827 | Individual Protein | Pyrimidinergic receptor P2Y4 | Homo sapiens | Kb | = | 708 | nM | 17302398 |
NPT2757 | Individual Protein | Purinergic receptor P2Y12 | Homo sapiens | Inhibition | = | 63 | % | 18232657 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 95.8 | nM | 19419204 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 1000 | nM | 19419204 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | Ratio EC50 | = | 4 | 19419204 | |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | Ratio EC50 | = | 2 | 19419204 | |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 63.1 | nM | 19419204 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 30.1 | nM | 19419204 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 239 | nM | 19419204 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 183 | nM | 19419204 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 237 | nM | 19419204 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 11700 | nM | 19419204 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 299 | nM | 19419204 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 111 | nM | 19419204 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 120 | nM | 19419204 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | > | 300000 | nM | 19419204 |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | Ratio EC50 | = | 3 | 19419204 | |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | Ratio EC50 | = | 10 | 19419204 | |
NPT2 | Others | Unspecified | IC50 | = | 500 | nM | 19256508 | |
NPT2 | Others | Unspecified | IC50 | > | 400000 | nM | 19256508 | |
NPT3826 | Individual Protein | Purinergic receptor P2Y2 | Homo sapiens | EC50 | = | 85 | nM | 19419868 |
NPT1441 | Individual Protein | MAP kinase-activated protein kinase 2 | Homo sapiens | IC50 | = | 2800 | nM | 19919896 |
NPT1441 | Individual Protein | MAP kinase-activated protein kinase 2 | Homo sapiens | IC50 | = | 6300 | nM | 19919896 |
NPT1441 | Individual Protein | MAP kinase-activated protein kinase 2 | Homo sapiens | IC50 | = | 12000 | nM | 19919896 |
NPT3825 | Individual Protein | Purinergic receptor P2Y1 | Homo sapiens | EC50 | = | 200 | nM | 20175517 |
NPT2 | Others | Unspecified | Kd | = | 134000 | nM | 20964406 | |
NPT483 | Individual Protein | Prelamin-A/C | Homo sapiens | Potency | = | 5 | nM | PubChem BioAssay data set |
NPT4848 | Individual Protein | Heat shock 70 kDa protein 1 | Homo sapiens | IC50 | = | 3370 | nM | PubChem BioAssay data set |
NPT1224 | Individual Protein | Glyceraldehyde-3-phosphate dehydrogenase liver | Homo sapiens | IC50 | > | 100000 | nM | PubChem BioAssay data set |
NPT2604 | Individual Protein | Heat shock cognate 71 kDa protein | Homo sapiens | IC50 | = | 17300 | nM | PubChem BioAssay data set |
NPT62 | Individual Protein | 6-phospho-1-fructokinase | Trypanosoma brucei | Potency | 31622.8 | nM | PubChem BioAssay data set | |
NPT4325 | Individual Protein | Pantothenate synthetase | Mycobacterium tuberculosis | Activity | = | 42.6 | % | 21641210 |
NPT4325 | Individual Protein | Pantothenate synthetase | Mycobacterium tuberculosis | Activity | = | 9.77 | % | 21641210 |
NPT4325 | Individual Protein | Pantothenate synthetase | Mycobacterium tuberculosis | Activity | = | 2 | 10'10L/mol/s | 21641210 |
NPT3825 | Individual Protein | Purinergic receptor P2Y1 | Homo sapiens | EC50 | = | 150 | nM | 21090681 |
NPT3829 | Individual Protein | Purinergic receptor P2Y11 | Homo sapiens | EC50 | = | 3300 | nM | 21090681 |
NPT6 | Organism | Plasmodium falciparum | Plasmodium falciparum | Potency | 19011.5 | nM | PubChem BioAssay data set | |
NPT484 | Individual Protein | Luciferin 4-monooxygenase | Photinus pyralis | Potency | 11423.9 | nM | PubChem BioAssay data set | |
NPT101 | Individual Protein | Glucagon-like peptide 1 receptor | Homo sapiens | Potency | 25118.9 | nM | PubChem BioAssay data set | |
NPT4964 | Individual Protein | P2X purinoceptor 4 | Mus musculus | EC50 | = | 1000 | nM | 23075067 |
NPT2671 | Individual Protein | P2X purinoceptor 4 | Rattus norvegicus | EC50 | = | 1000 | nM | 23075067 |
NPT4954 | Individual Protein | P2X purinoceptor 4 | Homo sapiens | EC50 | = | 1000 | nM | 23075067 |
NPT3831 | Individual Protein | Purinergic receptor P2Y1 | Rattus norvegicus | EC50 | = | 200 | nM | 22873688 |
NPT616 | Cell Line | MDCK | Canis lupus familiaris | Activity | = | 132 | nM | 23163425 |
NPT681 | Cell Line | PC-12 | Rattus norvegicus | Inhibition | = | 45 | % | 23751098 |
NPT2 | Others | Unspecified | IC50 | = | 60000 | nM | 23751098 | |
NPT2 | Others | Unspecified | IC50 | > | 500000 | nM | 23751098 | |
NPT3829 | Individual Protein | Purinergic receptor P2Y11 | Homo sapiens | EC50 | = | 6700 | nM | 23751098 |
NPT3825 | Individual Protein | Purinergic receptor P2Y1 | Homo sapiens | EC50 | = | 850 | nM | 23751098 |
NPT2 | Others | Unspecified | Ki | = | 18 | nM | 23403082 | |
NPT2 | Others | Unspecified | IC50 | = | 18 | nM | 23403082 | |
NPT2 | Others | Unspecified | Inhibition | = | 22 | % | 23403082 | |
NPT4505 | Individual Protein | Heat shock protein 75 kDa, mitochondrial | Homo sapiens | Activity | = | 31.3 | nM | 23965125 |
NPT2 | Others | Unspecified | Ratio | = | 10 | 23965125 | ||
NPT4504 | Individual Protein | Endoplasmin | Homo sapiens | Activity | = | 3.4 | nM | 23965125 |
NPT2264 | Protein Family | Heat shock protein HSP90 | Homo sapiens | Activity | = | 0.84 | nM | 23965125 |
NPT4505 | Individual Protein | Heat shock protein 75 kDa, mitochondrial | Homo sapiens | IC50 | = | 31303 | nM | 23965125 |
NPT4500 | Individual Protein | Heat shock protein 90 beta | Canis lupus familiaris | IC50 | = | 3241 | nM | 23965125 |
NPT1429 | Individual Protein | Heat shock protein HSP 90-beta | Homo sapiens | IC50 | = | 893677 | nM | 23965125 |
NPT918 | Individual Protein | Heat shock protein HSP 90-alpha | Homo sapiens | IC50 | = | 861330 | nM | 23965125 |
NPT2 | Others | Unspecified | Potency | 4771.6 | nM | PubChem BioAssay data set | ||
NPT2 | Others | Unspecified | Potency | 26603.2 | nM | PubChem BioAssay data set | ||
NPT2 | Others | Unspecified | Potency | 2984.9 | nM | PubChem BioAssay data set | ||
NPT2 | Others | Unspecified | Potency | 21313.8 | nM | PubChem BioAssay data set | ||
NPT2 | Others | Unspecified | Potency | 6007 | nM | PubChem BioAssay data set | ||
NPT2 | Others | Unspecified | Potency | 11883.2 | nM | PubChem BioAssay data set | ||
NPT2 | Others | Unspecified | Potency | 9439.2 | nM | PubChem BioAssay data set | ||
NPT2 | Others | Unspecified | Potency | 14960.1 | nM | PubChem BioAssay data set | ||
NPT4216 | Individual Protein | Thymidine kinase, cytosolic | Cricetulus griseus | Activity | = | 100 | % | 458818 |
NPT1755 | Individual Protein | Thymidine kinase, cytosolic | Homo sapiens | Activity | = | 100 | % | 458818 |
NPT4863 | Individual Protein | Thymidine kinase, mitochondrial | Homo sapiens | Activity | = | 100 | % | 458818 |
NPT3825 | Individual Protein | Purinergic receptor P2Y1 | Homo sapiens | EC50 | = | 850 | nM | 24846781 |
NPT2603 | Individual Protein | Adenosine kinase | Homo sapiens | Activity | = | 100 | % | 25259627 |
NPT2603 | Individual Protein | Adenosine kinase | Homo sapiens | Activity | < | 1 | % | 25259627 |
NPT2 | Others | Unspecified | Activity | = | 100 | % | 25259627 | |
NPT2 | Others | Unspecified | Activity | = | 57 | % | 25259627 | |
NPT2 | Others | Unspecified | Activity | = | 24 | % | 25259627 | |
NPT1434 | Individual Protein | Serine/threonine-protein kinase B-raf | Homo sapiens | Ratio | = | 0.64 | 25611072 | |
NPT1434 | Individual Protein | Serine/threonine-protein kinase B-raf | Homo sapiens | Ratio | = | 0.78 | 25611072 | |
NPT1434 | Individual Protein | Serine/threonine-protein kinase B-raf | Homo sapiens | Ratio | = | 0.97 | 25611072 | |
NPT1434 | Individual Protein | Serine/threonine-protein kinase B-raf | Homo sapiens | Ratio | = | 0.76 | 25611072 | |
NPT1434 | Individual Protein | Serine/threonine-protein kinase B-raf | Homo sapiens | Ratio | = | 0.75 | 25611072 | |
NPT1434 | Individual Protein | Serine/threonine-protein kinase B-raf | Homo sapiens | Ratio | = | 0.68 | 25611072 | |
NPT1434 | Individual Protein | Serine/threonine-protein kinase B-raf | Homo sapiens | Ratio | = | 0.62 | 25611072 | |
NPT1434 | Individual Protein | Serine/threonine-protein kinase B-raf | Homo sapiens | Ratio | = | 0.34 | 25611072 | |
NPT1434 | Individual Protein | Serine/threonine-protein kinase B-raf | Homo sapiens | Ratio | = | 0.54 | 25611072 | |
NPT1434 | Individual Protein | Serine/threonine-protein kinase B-raf | Homo sapiens | Ratio | = | 0.81 | 25611072 | |
NPT1434 | Individual Protein | Serine/threonine-protein kinase B-raf | Homo sapiens | Ratio | = | 1.16 | 25611072 | |
NPT1434 | Individual Protein | Serine/threonine-protein kinase B-raf | Homo sapiens | Ratio | = | 0.77 | 25611072 | |
NPT1434 | Individual Protein | Serine/threonine-protein kinase B-raf | Homo sapiens | Ratio | = | 0.72 | 25611072 | |
NPT1434 | Individual Protein | Serine/threonine-protein kinase B-raf | Homo sapiens | Ratio | = | 0.57 | 25611072 | |
NPT1434 | Individual Protein | Serine/threonine-protein kinase B-raf | Homo sapiens | Ratio | = | 0.94 | 25611072 | |
NPT1434 | Individual Protein | Serine/threonine-protein kinase B-raf | Homo sapiens | Ratio | = | 0.95 | 25611072 | |
NPT2 | Others | Unspecified | Potency | 15089 | nM | PubChem BioAssay data set | ||
NPT3829 | Individual Protein | Purinergic receptor P2Y11 | Homo sapiens | EC50 | = | 6700 | nM | 26447940 |
NPT3825 | Individual Protein | Purinergic receptor P2Y1 | Homo sapiens | EC50 | = | 850 | nM | 26447940 |
NPT2 | Others | Unspecified | IC50 | = | 60000 | nM | 26447940 | |
NPT2757 | Individual Protein | Purinergic receptor P2Y12 | Homo sapiens | IC50 | = | 251188.64 | nM | 27133596 |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient
●  The left chart: Distribution of similarity level between NPC174802 and all remaining natural products in the NPASS database.
●  The right table: Most similar natural products (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Natural Product ID |
---|---|---|
0.9929 | High Similarity | NPC164952 |
0.9929 | High Similarity | NPC130586 |
0.986 | High Similarity | NPC226245 |
0.9787 | High Similarity | NPC161224 |
0.9787 | High Similarity | NPC211025 |
0.9787 | High Similarity | NPC85689 |
0.9787 | High Similarity | NPC185991 |
0.9718 | High Similarity | NPC321814 |
0.965 | High Similarity | NPC212551 |
0.965 | High Similarity | NPC302778 |
0.9586 | High Similarity | NPC316618 |
0.9574 | High Similarity | NPC121222 |
0.9527 | High Similarity | NPC323091 |
0.9517 | High Similarity | NPC224076 |
0.9362 | High Similarity | NPC156461 |
0.9362 | High Similarity | NPC21448 |
0.9362 | High Similarity | NPC107374 |
0.9296 | High Similarity | NPC164665 |
0.9296 | High Similarity | NPC189068 |
0.9231 | High Similarity | NPC309832 |
0.9231 | High Similarity | NPC219313 |
0.9231 | High Similarity | NPC269827 |
0.922 | High Similarity | NPC229974 |
0.9078 | High Similarity | NPC209525 |
0.9078 | High Similarity | NPC161659 |
0.9038 | High Similarity | NPC326529 |
0.8981 | High Similarity | NPC324198 |
0.8981 | High Similarity | NPC319100 |
0.8981 | High Similarity | NPC189261 |
0.8961 | High Similarity | NPC321458 |
0.8961 | High Similarity | NPC324033 |
0.8951 | High Similarity | NPC314152 |
0.8944 | High Similarity | NPC317821 |
0.8919 | High Similarity | NPC472816 |
0.8903 | High Similarity | NPC326082 |
0.8896 | High Similarity | NPC261595 |
0.8808 | High Similarity | NPC239737 |
0.8667 | High Similarity | NPC207633 |
0.8611 | High Similarity | NPC129756 |
0.8533 | High Similarity | NPC150853 |
0.8467 | Intermediate Similarity | NPC136349 |
0.8442 | Intermediate Similarity | NPC311197 |
0.8442 | Intermediate Similarity | NPC54320 |
0.8442 | Intermediate Similarity | NPC313754 |
0.8421 | Intermediate Similarity | NPC328479 |
0.8414 | Intermediate Similarity | NPC30326 |
0.8389 | Intermediate Similarity | NPC64705 |
0.8389 | Intermediate Similarity | NPC232408 |
0.8377 | Intermediate Similarity | NPC52238 |
0.8322 | Intermediate Similarity | NPC177169 |
0.8322 | Intermediate Similarity | NPC317746 |
0.8288 | Intermediate Similarity | NPC33996 |
0.8276 | Intermediate Similarity | NPC320818 |
0.8255 | Intermediate Similarity | NPC211820 |
0.8255 | Intermediate Similarity | NPC251233 |
0.8255 | Intermediate Similarity | NPC318590 |
0.82 | Intermediate Similarity | NPC89147 |
0.82 | Intermediate Similarity | NPC274384 |
0.8153 | Intermediate Similarity | NPC195140 |
0.8121 | Intermediate Similarity | NPC186619 |
0.8052 | Intermediate Similarity | NPC326694 |
0.8012 | Intermediate Similarity | NPC324484 |
0.7975 | Intermediate Similarity | NPC93365 |
0.7975 | Intermediate Similarity | NPC290959 |
0.7963 | Intermediate Similarity | NPC325906 |
0.7888 | Intermediate Similarity | NPC14590 |
0.7785 | Intermediate Similarity | NPC61198 |
0.7718 | Intermediate Similarity | NPC262926 |
0.7679 | Intermediate Similarity | NPC313897 |
0.761 | Intermediate Similarity | NPC321052 |
0.7572 | Intermediate Similarity | NPC24589 |
0.7543 | Intermediate Similarity | NPC78941 |
0.7543 | Intermediate Similarity | NPC282458 |
0.7533 | Intermediate Similarity | NPC319221 |
0.7467 | Intermediate Similarity | NPC324009 |
0.7372 | Intermediate Similarity | NPC74306 |
0.7372 | Intermediate Similarity | NPC315642 |
0.7247 | Intermediate Similarity | NPC313514 |
0.7118 | Intermediate Similarity | NPC33382 |
0.7076 | Intermediate Similarity | NPC125659 |
0.7076 | Intermediate Similarity | NPC168702 |
0.7059 | Intermediate Similarity | NPC276373 |
0.7021 | Intermediate Similarity | NPC5802 |
0.7015 | Intermediate Similarity | NPC107160 |
0.6994 | Remote Similarity | NPC222174 |
0.6984 | Remote Similarity | NPC157821 |
0.6912 | Remote Similarity | NPC21461 |
0.6882 | Remote Similarity | NPC321393 |
0.6812 | Remote Similarity | NPC158055 |
0.6779 | Remote Similarity | NPC327579 |
0.6584 | Remote Similarity | NPC250178 |
0.6582 | Remote Similarity | NPC57279 |
0.6573 | Remote Similarity | NPC476564 |
0.6561 | Remote Similarity | NPC104011 |
0.6561 | Remote Similarity | NPC246193 |
0.6479 | Remote Similarity | NPC174114 |
0.6479 | Remote Similarity | NPC87981 |
0.6452 | Remote Similarity | NPC248007 |
0.6351 | Remote Similarity | NPC312187 |
0.6351 | Remote Similarity | NPC4837 |
0.6294 | Remote Similarity | NPC103388 |
0.6274 | Remote Similarity | NPC160666 |
0.6258 | Remote Similarity | NPC139776 |
0.625 | Remote Similarity | NPC287876 |
0.6207 | Remote Similarity | NPC472834 |
0.6188 | Remote Similarity | NPC14330 |
0.6122 | Remote Similarity | NPC18335 |
0.5975 | Remote Similarity | NPC109322 |
0.5936 | Remote Similarity | NPC164845 |
0.5906 | Remote Similarity | NPC217656 |
0.5897 | Remote Similarity | NPC68938 |
0.5872 | Remote Similarity | NPC89139 |
0.5858 | Remote Similarity | NPC296437 |
0.5824 | Remote Similarity | NPC470266 |
0.5813 | Remote Similarity | NPC5707 |
0.5806 | Remote Similarity | NPC313547 |
0.5771 | Remote Similarity | NPC244700 |
0.5756 | Remote Similarity | NPC476433 |
0.5756 | Remote Similarity | NPC476528 |
0.5741 | Remote Similarity | NPC180493 |
0.5723 | Remote Similarity | NPC474986 |
0.5723 | Remote Similarity | NPC476520 |
0.5723 | Remote Similarity | NPC476522 |
0.5723 | Remote Similarity | NPC476013 |
0.5722 | Remote Similarity | NPC472833 |
0.5722 | Remote Similarity | NPC265111 |
0.5714 | Remote Similarity | NPC476408 |
0.5696 | Remote Similarity | NPC189314 |
0.569 | Remote Similarity | NPC476521 |
0.5677 | Remote Similarity | NPC473585 |
0.5667 | Remote Similarity | NPC476561 |
0.5628 | Remote Similarity | NPC472832 |
0.5628 | Remote Similarity | NPC18308 |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules.
●  The left chart: Distribution of similarity level between NPC174802 and all drugs/candidates.
●  The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Drug ID | Developmental Stage |
---|---|---|---|
1.0 | High Similarity | NPD339 | Approved |
0.9929 | High Similarity | NPD338 | Approved |
0.9787 | High Similarity | NPD283 | Approved |
0.965 | High Similarity | NPD242 | Approved |
0.9517 | High Similarity | NPD169 | Phase 2 |
0.9362 | High Similarity | NPD249 | Approved |
0.9362 | High Similarity | NPD250 | Approved |
0.9231 | High Similarity | NPD195 | Approved |
0.9231 | High Similarity | NPD186 | Discovery |
0.8986 | High Similarity | NPD3107 | Discontinued |
0.8986 | High Similarity | NPD1750 | Clinical (unspecified phase) |
0.8986 | High Similarity | NPD1369 | Phase 2 |
0.8981 | High Similarity | NPD4171 | Clinical (unspecified phase) |
0.8951 | High Similarity | NPD185 | Approved |
0.8924 | High Similarity | NPD1412 | Clinical (unspecified phase) |
0.8896 | High Similarity | NPD247 | Clinical (unspecified phase) |
0.8896 | High Similarity | NPD7988 | Suspended |
0.8828 | High Similarity | NPD166 | Approved |
0.8812 | High Similarity | NPD4716 | Approved |
0.8811 | High Similarity | NPD193 | Suspended |
0.8808 | High Similarity | NPD2624 | Phase 2 |
0.8808 | High Similarity | NPD2646 | Discontinued |
0.8808 | High Similarity | NPD1732 | Phase 3 |
0.8758 | High Similarity | NPD4744 | Clinical (unspecified phase) |
0.8701 | High Similarity | NPD3083 | Approved |
0.8545 | High Similarity | NPD6417 | Clinical (unspecified phase) |
0.8467 | Intermediate Similarity | NPD548 | Clinical (unspecified phase) |
0.8443 | Intermediate Similarity | NPD2632 | Approved |
0.8443 | Intermediate Similarity | NPD2631 | Clinical (unspecified phase) |
0.8443 | Intermediate Similarity | NPD2630 | Approved |
0.8442 | Intermediate Similarity | NPD220 | Clinical (unspecified phase) |
0.8442 | Intermediate Similarity | NPD218 | Approved |
0.8442 | Intermediate Similarity | NPD217 | Approved |
0.8442 | Intermediate Similarity | NPD216 | Approved |
0.8442 | Intermediate Similarity | NPD219 | Phase 3 |
0.8365 | Intermediate Similarity | NPD2647 | Phase 3 |
0.8247 | Intermediate Similarity | NPD214 | Approved |
0.8247 | Intermediate Similarity | NPD213 | Clinical (unspecified phase) |
0.811 | Intermediate Similarity | NPD5666 | Phase 2 |
0.8079 | Intermediate Similarity | NPD7158 | Phase 1 |
0.8056 | Intermediate Similarity | NPD248 | Discontinued |
0.7986 | Intermediate Similarity | NPD9633 | Phase 3 |
0.7975 | Intermediate Similarity | NPD546 | Clinical (unspecified phase) |
0.7963 | Intermediate Similarity | NPD1776 | Approved |
0.7963 | Intermediate Similarity | NPD1777 | Approved |
0.7935 | Intermediate Similarity | NPD3085 | Phase 1 |
0.7931 | Intermediate Similarity | NPD9632 | Phase 3 |
0.7925 | Intermediate Similarity | NPD4074 | Clinical (unspecified phase) |
0.7917 | Intermediate Similarity | NPD870 | Clinical (unspecified phase) |
0.7902 | Intermediate Similarity | NPD9408 | Phase 3 |
0.7885 | Intermediate Similarity | NPD3086 | Phase 3 |
0.7785 | Intermediate Similarity | NPD252 | Clinical (unspecified phase) |
0.7778 | Intermediate Similarity | NPD1692 | Approved |
0.7697 | Intermediate Similarity | NPD3696 | Approved |
0.7697 | Intermediate Similarity | NPD3695 | Approved |
0.7688 | Intermediate Similarity | NPD5683 | Clinical (unspecified phase) |
0.7688 | Intermediate Similarity | NPD5682 | Phase 3 |
0.7688 | Intermediate Similarity | NPD5684 | Clinical (unspecified phase) |
0.7657 | Intermediate Similarity | NPD4054 | Clinical (unspecified phase) |
0.7607 | Intermediate Similarity | NPD516 | Clinical (unspecified phase) |
0.7582 | Intermediate Similarity | NPD549 | Approved |
0.7483 | Intermediate Similarity | NPD194 | Clinical (unspecified phase) |
0.7391 | Intermediate Similarity | NPD536 | Clinical (unspecified phase) |
0.7372 | Intermediate Similarity | NPD582 | Approved |
0.7325 | Intermediate Similarity | NPD4240 | Approved |
0.7267 | Intermediate Similarity | NPD3708 | Phase 2 |
0.7247 | Intermediate Similarity | NPD7138 | Phase 2 |
0.7222 | Intermediate Similarity | NPD353 | Discontinued |
0.7191 | Intermediate Similarity | NPD1063 | Phase 2 |
0.717 | Intermediate Similarity | NPD171 | Discontinued |
0.7037 | Intermediate Similarity | NPD2965 | Clinical (unspecified phase) |
0.7 | Intermediate Similarity | NPD2877 | Clinical (unspecified phase) |
0.7 | Intermediate Similarity | NPD2876 | Phase 3 |
0.699 | Remote Similarity | NPD5080 | Phase 2 |
0.697 | Remote Similarity | NPD231 | Clinical (unspecified phase) |
0.6939 | Remote Similarity | NPD5079 | Phase 2 |
0.6927 | Remote Similarity | NPD2824 | Phase 2 |
0.6867 | Remote Similarity | NPD9605 | Phase 3 |
0.6854 | Remote Similarity | NPD1046 | Clinical (unspecified phase) |
0.6824 | Remote Similarity | NPD9606 | Approved |
0.6812 | Remote Similarity | NPD6840 | Approved |
0.6786 | Remote Similarity | NPD2902 | Phase 2 |
0.6786 | Remote Similarity | NPD2903 | Clinical (unspecified phase) |
0.6779 | Remote Similarity | NPD9607 | Approved |
0.6684 | Remote Similarity | NPD4495 | Phase 1 |
0.6646 | Remote Similarity | NPD209 | Clinical (unspecified phase) |
0.6623 | Remote Similarity | NPD9409 | Discontinued |
0.6606 | Remote Similarity | NPD1730 | Discontinued |
0.6582 | Remote Similarity | NPD545 | Clinical (unspecified phase) |
0.6514 | Remote Similarity | NPD527 | Clinical (unspecified phase) |
0.651 | Remote Similarity | NPD9374 | Approved |
0.65 | Remote Similarity | NPD1119 | Phase 2 |
0.6486 | Remote Similarity | NPD9373 | Approved |
0.6478 | Remote Similarity | NPD547 | Clinical (unspecified phase) |
0.6452 | Remote Similarity | NPD9084 | Phase 2 |
0.6447 | Remote Similarity | NPD307 | Approved |
0.6415 | Remote Similarity | NPD282 | Approved |
0.6383 | Remote Similarity | NPD2152 | Clinical (unspecified phase) |
0.6364 | Remote Similarity | NPD1431 | Approved |
0.6364 | Remote Similarity | NPD2253 | Discontinued |
0.6364 | Remote Similarity | NPD1430 | Approved |
0.6335 | Remote Similarity | NPD1058 | Discontinued |
0.6331 | Remote Similarity | NPD775 | Approved |
0.6276 | Remote Similarity | NPD4458 | Phase 2 |
0.6276 | Remote Similarity | NPD4459 | Clinical (unspecified phase) |
0.6272 | Remote Similarity | NPD7531 | Clinical (unspecified phase) |
0.625 | Remote Similarity | NPD8829 | Clinical (unspecified phase) |
0.6235 | Remote Similarity | NPD9083 | Clinical (unspecified phase) |
0.6226 | Remote Similarity | NPD1128 | Approved |
0.6226 | Remote Similarity | NPD1127 | Approved |
0.6211 | Remote Similarity | NPD207 | Discontinued |
0.6184 | Remote Similarity | NPD9584 | Phase 2 |
0.6182 | Remote Similarity | NPD799 | Phase 1 |
0.6182 | Remote Similarity | NPD1808 | Phase 1 |
0.6124 | Remote Similarity | NPD6381 | Phase 2 |
0.6122 | Remote Similarity | NPD8836 | Approved |
0.6121 | Remote Similarity | NPD6112 | Approved |
0.6108 | Remote Similarity | NPD1118 | Discontinued |
0.6101 | Remote Similarity | NPD281 | Approved |
0.6076 | Remote Similarity | NPD798 | Discontinued |
0.6061 | Remote Similarity | NPD1121 | Approved |
0.6061 | Remote Similarity | NPD1120 | Approved |
0.6 | Remote Similarity | NPD9417 | Phase 3 |
0.6 | Remote Similarity | NPD5486 | Discontinued |
0.6 | Remote Similarity | NPD9416 | Phase 3 |
0.6 | Remote Similarity | NPD2593 | Clinical (unspecified phase) |
0.5987 | Remote Similarity | NPD9375 | Discontinued |
0.597 | Remote Similarity | NPD4714 | Approved |
0.597 | Remote Similarity | NPD4713 | Clinical (unspecified phase) |
0.597 | Remote Similarity | NPD34 | Approved |
0.597 | Remote Similarity | NPD4715 | Clinical (unspecified phase) |
0.5964 | Remote Similarity | NPD535 | Approved |
0.5963 | Remote Similarity | NPD7502 | Clinical (unspecified phase) |
0.5941 | Remote Similarity | NPD1117 | Clinical (unspecified phase) |
0.5933 | Remote Similarity | NPD1816 | Clinical (unspecified phase) |
0.5924 | Remote Similarity | NPD9582 | Phase 3 |
0.5911 | Remote Similarity | NPD8250 | Phase 2 |
0.5911 | Remote Similarity | NPD5458 | Discontinued |
0.5906 | Remote Similarity | NPD9626 | Clinical (unspecified phase) |
0.5904 | Remote Similarity | NPD9484 | Clinical (unspecified phase) |
0.5882 | Remote Similarity | NPD2452 | Phase 2 |
0.5882 | Remote Similarity | NPD2450 | Phase 2 |
0.5882 | Remote Similarity | NPD2453 | Phase 2 |
0.5882 | Remote Similarity | NPD2451 | Phase 2 |
0.5869 | Remote Similarity | NPD6036 | Suspended |
0.5864 | Remote Similarity | NPD515 | Phase 1 |
0.5852 | Remote Similarity | NPD7842 | Phase 2 |
0.5829 | Remote Similarity | NPD691 | Discontinued |
0.5813 | Remote Similarity | NPD8830 | Phase 3 |
0.5805 | Remote Similarity | NPD796 | Phase 2 |
0.5769 | Remote Similarity | NPD9406 | Approved |
0.5741 | Remote Similarity | NPD78 | Approved |
0.5741 | Remote Similarity | NPD9544 | Approved |
0.5738 | Remote Similarity | NPD5768 | Phase 2 |
0.5727 | Remote Similarity | NPD5627 | Approved |
0.5696 | Remote Similarity | NPD1368 | Approved |
0.5696 | Remote Similarity | NPD8831 | Approved |
0.5696 | Remote Similarity | NPD8833 | Approved |
0.5693 | Remote Similarity | NPD5665 | Clinical (unspecified phase) |
0.5677 | Remote Similarity | NPD6351 | Discovery |
0.5671 | Remote Similarity | NPD1775 | Approved |
0.5671 | Remote Similarity | NPD1085 | Approved |
0.567 | Remote Similarity | NPD3849 | Clinical (unspecified phase) |
0.5669 | Remote Similarity | NPD757 | Phase 3 |
0.566 | Remote Similarity | NPD9360 | Approved |
0.5655 | Remote Similarity | NPD5340 | Clinical (unspecified phase) |
0.5654 | Remote Similarity | NPD534 | Phase 2 |
0.5654 | Remote Similarity | NPD537 | Phase 2 |
0.5654 | Remote Similarity | NPD4555 | Clinical (unspecified phase) |
0.5652 | Remote Similarity | NPD2221 | Clinical (unspecified phase) |
0.5635 | Remote Similarity | NPD1017 | Clinical (unspecified phase) |
0.5612 | Remote Similarity | NPD3913 | Clinical (unspecified phase) |
0.5607 | Remote Similarity | NPD6023 | Discontinued |
0.5604 | Remote Similarity | NPD3697 | Discontinued |
PubChem CID   | 5957 |
ChEMBL   | CHEMBL14249 |
ZINC   |
Molecular Weight:   | 507.00 |
ALogP:   | -2.7745 |
MLogP:   | 0.25 |
XLogP:   | -5.925 |
# Rotatable Bonds:   | 15 |
Polar Surface Area:   | 308.56 |
# H-Bond Aceptor:   | 18 |
# H-Bond Donor:   | 7 |
# Rings:   | 3 |
# Heavy Atoms:   | 31 |